Literature DB >> 18796307

Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression.

Yukio Ago1, Shinsuke Arikawa, Miyuki Yata, Koji Yano, Michikazu Abe, Kazuhiro Takuma, Toshio Matsuda.   

Abstract

Chronic corticosterone and isolation rearing paradigms may provide reliable mouse models of depression. Using these models, the present study examined if the specific glucocorticoid receptor antagonist, RU-43044, has an antidepressant-like effect, and studied the possible role of prefrontal neurotransmission on the behavioral effects. Chronic administration of corticosterone and isolation rearing increased the immobility time in the forced swim and tail suspension tests. Subchronic treatment with RU-43044 decreased the immobility time in the forced swim test in chronic corticosterone-treated and isolation-reared mice, but not the control mice. Chronic corticosterone decreased the levels of cortical glucocorticoid receptors and stress-induced increases in plasma corticosterone levels, and blocked the response of plasma corticosterone to dexamethasone, while isolation rearing did not cause any changes in the glucocorticoid receptor system. Both chronic corticosterone and isolation rearing markedly increased high K+ -induced dopamine release, but not serotonin release, in the prefrontal cortex. Subchronic RU-43044 reversed the enhanced release of dopamine in the prefrontal cortex of chronic corticosterone-treated and isolation-reared mice. These results suggest that chronic corticosterone and isolation rearing increase the depressive-like behavior in glucocorticoid receptor-dependent and independent manners, respectively, and that RU-43044 shows an antidepressant-like effect, probably via an inhibition of enhanced prefrontal dopaminergic neurotransmission in these mouse models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18796307     DOI: 10.1016/j.neuropharm.2008.08.026

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  23 in total

1.  Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Authors:  Thibault Renoir; Terence Y C Pang; Michelle S Zajac; Grace Chan; Xin Du; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Glucocorticoid receptors in the prefrontal cortex regulate stress-evoked dopamine efflux and aspects of executive function.

Authors:  Kelly A Butts; Joanne Weinberg; Allan H Young; Anthony G Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-27       Impact factor: 11.205

3.  Involvement of spinal 5-HT1A receptors in isolation rearing-induced hypoalgesia in mice.

Authors:  Naotaka Horiguchi; Yukio Ago; Kazuki Asada; Yuki Kita; Naoki Hiramatsu; Kazuhiro Takuma; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2012-12-29       Impact factor: 4.530

4.  Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation.

Authors:  K Koda; Y Ago; K Yano; M Nishimura; H Kobayashi; A Fukada; K Takuma; T Matsuda
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

5.  Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids.

Authors:  Minae Niwa; Hanna Jaaro-Peled; Stephanie Tankou; Saurav Seshadri; Takatoshi Hikida; Yurie Matsumoto; Nicola G Cascella; Shin-ichi Kano; Norio Ozaki; Toshitaka Nabeshima; Akira Sawa
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

6.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

7.  Role of social encounter-induced activation of prefrontal serotonergic systems in the abnormal behaviors of isolation-reared mice.

Authors:  Yukio Ago; Ryota Araki; Tatsunori Tanaka; Asuka Sasaga; Saki Nishiyama; Kazuhiro Takuma; Toshio Matsuda
Journal:  Neuropsychopharmacology       Date:  2013-02-20       Impact factor: 7.853

Review 8.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

9.  Sensitivity of depression-like behavior to glucocorticoids and antidepressants is independent of forebrain glucocorticoid receptors.

Authors:  Melanie Y Vincent; Rifat J Hussain; Michael E Zampi; Katherine Sheeran; Matia B Solomon; James P Herman; Anum Khan; Lauren Jacobson
Journal:  Brain Res       Date:  2013-05-28       Impact factor: 3.252

10.  Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.

Authors:  Francis L Pazini; Mauricio P Cunha; Julia M Rosa; André R S Colla; Vicente Lieberknecht; Ágatha Oliveira; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2015-12-11       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.